Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
- Introduction and basic biology of NK cells; history, basic biology, mode of function, Innate Lymphoid Cells (ILCs), mouse models of human cancer, NK cells in metastatic cancer and targeting cancer stem cells and use in Immunotherapy
2. Immunotherapy using CAR/NK with and without CAR/T: What we have learned from Trials and where are we heading
3. Immunotherapy using NK cells with and without T cells and Tumor infiltrating lymphocytes as well as NK/T cells : Different sources of NK cells (cord blood derived NK cells, iPSC derived NK cells, NK cell lines, different feeder cell expanded peripheral blood NK cells), types of activation and expansion and Successes and Challenges of each source
4. Autologous vs allogeneic sources of NK and T cell effectors; Studies of patients’ NK and T cell function and the challenges of using autologous sources
5. Reversing NK inhibitory tumor microenvironment by targeting suppressive immune effectors; Multiparameter analyses of data, Reference tools for immune fitness analyses. Immunogenetic analyses of immune cells and Correlates with tumor cell profiling
6. Check point inhibitors: Novel approaches for use with NK cell immunotherapy
7. Combination of NK immunotherapy with chemotherapy and radiation: The rationale and background
8. NK cell immunotherapy using ADCC inducing antibodies
9. Oncolytic viruses and NK cell immunotherapy: successes and challenges
10. NK cell diagnostics; Different tests to assess patient NK function
11. Novel cell delivery systems; Intravenous vs. intraperitoneal and intracranial
NK cells in cancer immunotherapy: Successes and Challenges explains the latest immunotherapeutic strategies, focusing on NK cells to allow the best and precise combination treatments to cancer patients. The book provides existing background knowledge in the field of immunotherapy and discusses future areas of research required to carry out cutting-edge, validated therapies. Chapters cover advances in immunotherapeutic strategies, in particular, the use of NK cells with and without T-cell therapy in the treatment of cancer. The book is a valuable resource for cancer researchers, oncologists, graduate students and those interested in learning more about novel strategies to treat cancer patients.
Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective.
- Covers CAR/T and CAR/NK and adoptive NK cell therapy with and without T cell therapies
- Discusses basic biology of NK cells and mouse models of human cancers and the role of NK cells in metastatic cancer and in cancer stem cells
- Encompasses information on combination therapies using check point inhibition, adoptive transfer of cytotoxic effector cells, chemotherapeutic drugs and activating and inhibitory antibodies
Cancer researchers, medical scientists, clinicians, graduate students
- No. of pages:
- © Academic Press 2021
- 1st March 2021
- Academic Press
- Hardcover ISBN:
Dr. Anahid Jewett is well-known nationally and internationally for her contribution to the field of NK biology, tumor immunology and cancer immunotherapy. She serves on the editorial board of many prestigious journals and has been a reviewer on the board of National Institute of Health study sections. She holds several patents and has published more than 100 high impact journal articles, reviews, commentaries and book chapters in the field of cancer. Dr. Jewett’s major contributions to science and NK cell biology were the identification, characterization and the establishment of the concept of split anergy in NK cells, establishment of the role of NK cells in elimination, selection and differentiation of cancer stem cells as well as healthy stem cells, and methods to generate large numbers of super-charged NK cells which are in use currently in clinical trials of cancer patients.
National Institute of Health Study Sections, UCLA, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.